This further reduction in SDMA was paralleled by robust effects on sensitivity and net cell growth/death, suggesting that PRMT5 inhibitors are effective at inducing cytotoxicity in the majority of p53 wild-type lymphoma cell lines with various kinetics that mirror SDMA inhibition. This evidence concerns the gene TP53 and lymphoma.